Literature DB >> 24772298

Clinical applications of nucleic acid aptamers in cancer.

Xiaoyu Pei1, Jun Zhang1, Jie Liu2.   

Abstract

Nucleic acid aptamers are small single-stranded DNA or RNA oligonucleotide segments, which bind to their targets with high affinity and specificity via unique three-dimensional structures. Aptamers are generated by an iterative in vitro selection process, termed as systematic evolution of ligands by exponential enrichment. Owing to their specificity, non-immunogenicity, non-toxicity, easily modified chemical structure and wide range of targets, aptamers appear to be ideal candidates for various clinical applications (diagnosis or treatment), such as cell detection, target diagnosis, molecular imaging and drug delivery. Several aptamers have entered the clinical pipeline for applications in diseases such as macular degeneration, coronary artery bypass graft surgery and various types of cancer. The aim of this review was to summarize and highlight the clinical applications of aptamers in cancer diagnosis and treatment.

Entities:  

Keywords:  aptamer; cancer diagnosis; cancer therapy; clinical application; systematic evolution of ligands by exponential enrichment

Year:  2014        PMID: 24772298      PMCID: PMC3999129          DOI: 10.3892/mco.2014.255

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  87 in total

1.  Escort aptamers: a delivery service for diagnosis and therapy.

Authors:  B J Hicke; A W Stephens
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

2.  In vitro selection of DNA aptamers to anthrax spores with electrochemiluminescence detection.

Authors:  J G Bruno; J L Kiel
Journal:  Biosens Bioelectron       Date:  1999-05-31       Impact factor: 10.618

3.  Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer.

Authors:  Ronak Savla; Oleh Taratula; Olga Garbuzenko; Tamara Minko
Journal:  J Control Release       Date:  2011-02-20       Impact factor: 9.776

4.  Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.

Authors:  James O McNamara; Eran R Andrechek; Yong Wang; Kristi D Viles; Rachel E Rempel; Eli Gilboa; Bruce A Sullenger; Paloma H Giangrande
Journal:  Nat Biotechnol       Date:  2006-06-25       Impact factor: 54.908

5.  In vitro selection and characterization of streptomycin-binding RNAs: recognition discrimination between antibiotics.

Authors:  S T Wallace; R Schroeder
Journal:  RNA       Date:  1998-01       Impact factor: 4.942

6.  Multifunctional oval-shaped gold-nanoparticle-based selective detection of breast cancer cells using simple colorimetric and highly sensitive two-photon scattering assay.

Authors:  Wentong Lu; Sri Ranjini Arumugam; Dulal Senapati; Anant K Singh; Tahir Arbneshi; Sadia Afrin Khan; Hongtao Yu; Paresh Chandra Ray
Journal:  ACS Nano       Date:  2010-03-23       Impact factor: 15.881

7.  First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity.

Authors:  Christopher K Dyke; Steven R Steinhubl; Neal S Kleiman; Richard O Cannon; Laura G Aberle; Min Lin; Shelley K Myles; Chiara Melloni; Robert A Harrington; John H Alexander; Richard C Becker; Christopher P Rusconi
Journal:  Circulation       Date:  2006-11-13       Impact factor: 29.690

8.  Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen.

Authors:  Shawn E Lupold; Brian J Hicke; Yun Lin; Donald S Coffey
Journal:  Cancer Res       Date:  2002-07-15       Impact factor: 12.701

Review 9.  Analysis of FDA approved anticancer drugs reveals the future of cancer therapy.

Authors:  Mikhail V Blagosklonny
Journal:  Cell Cycle       Date:  2004-08-16       Impact factor: 4.534

10.  The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells.

Authors:  Sridharan Soundararajan; Weiwei Chen; Eleanor K Spicer; Nigel Courtenay-Luck; Daniel J Fernandes
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

View more
  13 in total

1.  Single-stranded DNA aptamer targeting and neutralization of anti-D alloantibody: a potential therapeutic strategy for haemolytic diseases caused by Rhesus alloantibody.

Authors:  Yinze Zhang; Fan Wu; Manni Wang; Naibao Zhuang; Huayou Zhou; Hua Xu
Journal:  Blood Transfus       Date:  2016-11-11       Impact factor: 3.443

Review 2.  Aptamers in analytics.

Authors:  Muslum Ilgu; Marit Nilsen-Hamilton
Journal:  Analyst       Date:  2016-03-07       Impact factor: 4.616

Review 3.  Aptamer and its applications in neurodegenerative diseases.

Authors:  Jing Qu; Shuqing Yu; Yuan Zheng; Yan Zheng; Hui Yang; Jianliang Zhang
Journal:  Cell Mol Life Sci       Date:  2016-08-25       Impact factor: 9.261

4.  Superior Performance of Aptamer in Tumor Penetration over Antibody: Implication of Aptamer-Based Theranostics in Solid Tumors.

Authors:  Dongxi Xiang; Conglong Zheng; Shu-Feng Zhou; Shuxi Qiao; Phuong Ha-Lien Tran; Chunwen Pu; Yong Li; Lingxue Kong; Abbas Z Kouzani; Jia Lin; Ke Liu; Lianhong Li; Sarah Shigdar; Wei Duan
Journal:  Theranostics       Date:  2015-07-02       Impact factor: 11.556

Review 5.  Aptamers: A promising chemical antibody for cancer therapy.

Authors:  Gang Zhou; George Wilson; Lionel Hebbard; Wei Duan; Christopher Liddle; Jacob George; Liang Qiao
Journal:  Oncotarget       Date:  2016-03-22

6.  AS1411 Aptamer-Anionic Linear Globular Dendrimer G2-Iohexol Selective Nano-Theranostics.

Authors:  Pardis Mohammadzadeh; Reza Ahangari Cohan; Seyedeh Masoumeh Ghoreishi; Ahmad Bitarafan-Rajabi; Mehdi Shafiee Ardestani
Journal:  Sci Rep       Date:  2017-09-19       Impact factor: 4.379

7.  Specific and sensitive tumor imaging using biostable oligonucleotide aptamer probes.

Authors:  Zihua Zeng; Parag Parekh; Zheng Li; Zheng-Zheng Shi; Ching-Hsuan Tung; Youli Zu
Journal:  Theranostics       Date:  2014-07-19       Impact factor: 11.556

8.  Site specific replacements of a single loop nucleoside with a dibenzyl linker may switch the activity of TBA from anticoagulant to antiproliferative.

Authors:  Maria Scuotto; Elisa Rivieccio; Alessia Varone; Daniela Corda; Mariarosaria Bucci; Valentina Vellecco; Giuseppe Cirino; Antonella Virgilio; Veronica Esposito; Aldo Galeone; Nicola Borbone; Michela Varra; Luciano Mayol
Journal:  Nucleic Acids Res       Date:  2015-08-06       Impact factor: 16.971

9.  Aptamer-guided DNA tetrahedron as a novel targeted drug delivery system for MUC1-expressing breast cancer cells in vitro.

Authors:  Bindong Dai; Yan Hu; JinHong Duan; Xian-Da Yang
Journal:  Oncotarget       Date:  2016-06-21

10.  Intracellular Expression of PAI-1 Specific Aptamers Alters Breast Cancer Cell Migration, Invasion and Angiogenesis.

Authors:  Yolanda M Fortenberry; Stephanie M Brandal; Gilles Carpentier; Malvi Hemani; Arvind P Pathak
Journal:  PLoS One       Date:  2016-10-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.